In vivo assessment of the molecular mechanism of inhaled combination of beclomethasone and formoterol on cell differentiation factors and airway remodelling in COPD

Trial Profile

In vivo assessment of the molecular mechanism of inhaled combination of beclomethasone and formoterol on cell differentiation factors and airway remodelling in COPD

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 May 2015

At a glance

  • Drugs Beclometasone/formoterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top